Premium
NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report
Author(s) -
Herrlinger Ulrich,
Küker Wilhelm,
Uhl Martin,
Blaicher HansPeter,
Karnath HansOtto,
Kanz Lothar,
Bamberg Michael,
Weller Michael
Publication year - 2005
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20495
Subject(s) - primary central nervous system lymphoma , medicine , methotrexate , leukoencephalopathy , neurotoxicity , radiation therapy , central nervous system , lymphoma , quality of life (healthcare) , oncology , pediatrics , toxicity , disease , nursing
The NOA‐03 trial explored high‐dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole‐brain radiotherapy given at relapse ( p = 0.11). Attention deficits were found in all six tested patients, and memory deficits in four patients. Two patients had normal, three had moderately restricted, and one had markedly restricted quality of life. Thus, high‐dose methotrexate with deferred radiotherapy had only moderate efficacy and was associated with significant neurotoxicity in long‐term surviving patients. Ann Neurol 2005;57:843–847